Circulating levels and hepatic expression of molecular mediators of atherosclerosis in nonalcoholic fatty liver disease

Atherosclerosis

Volumn 209, Issue 2, 2010, Pages 585-591

  Sookoian, Silvia ^a,b,c   Castaño, Gustavo O ^b,c   Burgueño, Adriana L ^a   Rosselli, María Soledad ^a   Gianotti, Tomas Fernández ^a   Mallardi, Pablo ^d   Martino, Julio San ^d   Pirola, Carlos Jose ^a  

^a INSTITUTO DE INVESTIGACIONES MÉDICAS ALFREDO LANARI   (Argentina)

^b Research Council of GCBA   (Argentina)

^c Hospital General de Agudos Dr Abel Zubizarreta   (Argentina)

^d Hospital Diego Thompson   (Argentina)

Author keywords

Cardiovascular risk; CD40; Fatty liver; ICAM 1; NAFLD; NASH; Nonalcoholic steatohepatitis; PAI 1; SCD40L

Indexed keywords

CD40 LIGAND; INTERCELLULAR ADHESION MOLECULE 1; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATORY INFILTRATE; LIVER BIOPSY; LIVER HISTOLOGY; LIVER NECROSIS; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CD40 LIGAND; FATTY LIVER; FEMALE; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; LIVER; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1;

EID: 77950017450     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.10.011     Document Type: Article

References (31)

1. Marchesini G., Brizi M., Bianchi G., et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001, 50:1844-1850.
2. Targher G., Marra F., Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon?. Diabetologia 2008, 51:1947-1953.
3. Sookoian S., Pirola C.J. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J Hepatol 2008, 49:600-607.
4. Akabame S., Hamaguchi M., Tomiyasu K., et al. Evaluation of vulnerable coronary plaques and non-alcoholic fatty liver disease (NAFLD) by 64-detector multislice computed tomography (MSCT). Circ J 2008, 72:618-625.
5. Villanova N., Moscatiello S., Ramilli S., et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 2005, 42:473-480.
6. Targher G., Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 2007, 191:235-240.
7. Haukeland J.W., Damas J.K., Konopski Z., et al. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol 2006, 44:1167-1174.
8. Targher G., Bertolini L., Rodella S., et al. NASH predicts plasma inflammatory biomarkers independently of visceral fat in men. Obesity (Silver Spring) 2008, 16:1394-1399.
9. Wieckowska A., Papouchado B.G., Li Z., Lopez R., Zein N.N., Feldstein A.E. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol 2008, 103:1372-1379.
10. Yoneda M., Mawatari H., Fujita K., et al. High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J Gastroenterol 2007, 42:573-582.
11. Ito S., Yukawa T., Uetake S., Yamauchi M. Serum intercellular adhesion molecule-1 in patients with nonalcoholic steatohepatitis: comparison with alcoholic hepatitis. Alcohol Clin Exp Res 2007, 31:S83-S87.
12. Tilg H., Diehl A.M. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000, 343:1467-1476.
13. Rohde L.E., Hennekens C.H., Ridker P.M. Cross-sectional study of soluble intercellular adhesion molecule-1 and cardiovascular risk factors in apparently healthy men. Arterioscler Thromb Vasc Biol 1999, 19:1595-1599.
14. Lutgens E., Gorelik L., Daemen M.J., et al. Requirement for CD154 in the progression of atherosclerosis. Nat Med 1999, 5:1313-1316.
15. Thogersen A.M., Jansson J.H., Boman K., et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998, 98:2241-2247.
16. Kleiner D.E., Brunt E.M., Van N.M., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41:1313-1321.
17. Brunt E.M., Janney C.G., Di Bisceglie A.M., Neuschwander-Tetri B.A., Bacon B.R. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999, 94:2467-2474.
18. Neuschwander-Tetri B.A., Caldwell S.H. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 2003, 37:1202-1219.
19. Asselah T., Bieche I., Laurendeau I., et al. Significant gene expression differences in histologically " normal" liver biopsies: implications for control tissue. Hepatology 2008, 48:953-962.
20. Kotronen A., Yki-Jarvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008, 28:27-38.
21. Ekstedt M., Franzen L.E., Mathiesen U.L., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006, 44:865-873.
22. Targher G., Bertolini L., Scala L., et al. Plasma PAI-1 levels are increased in patients with nonalcoholic steatohepatitis. Diabetes Care 2007, 30:e31-e32.
23. Targher G., Bertolini L., Poli F., et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 2005, 54:3541-3546.
24. Burra P., Hubscher S.G., Shaw J., Elias E., Adams D.H. Is the intercellular adhesion molecule-1/leukocyte function associated antigen 1 pathway of leukocyte adhesion involved in the tissue damage of alcoholic hepatitis?. Gut 1992, 33:268-271.
25. Douds A.C., Lim A.G., Jazrawi R.P., Finlayson C., Maxwell J.D. Serum intercellular adhesion molecule-1 in alcoholic liver disease and its relationship with histological disease severity. J Hepatol 1997, 26:280-286.
26. Alessi M.C., Bastelica D., Mavri A., et al. Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation. Arterioscler Thromb Vasc Biol 2003, 23:1262-1268.
27. Rosselli M.S., Burgueno A.L., Carabelli J., Schuman M., Pirola C.J., Sookoian S. Losartan reduces liver expression of plasminogen activator inhibitor-1 (PAI-1) in a high fat-induced rat nonalcoholic fatty liver disease model. Atherosclerosis 2009, 206:119-126.
28. Thuy S., Ladurner R., Volynets V., et al. Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J Nutr 2008, 138:1452-1455.
29. Pontrelli P., Ursi M., Ranieri E., et al. CD40L proinflammatory and profibrotic effects on proximal tubular epithelial cells: role of NF-kappaB and lyn. J Am Soc Nephrol 2006, 17:627-636.
30. Grewal I.S., Flavell R.A. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998, 16:111-135.
31. Henn V., Slupsky J.R., Grafe M., et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998, 391:591-594.